Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
G610529-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
G610529-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,000.90 |
Synonyms | GDC-0134|UNII-4N6KQ7D685|RG-6000|4N6KQ7D685|1637394-01-4|2-Pyridinamine, 3-(difluoromethoxy)-5-(2-(3,3-difluoro-1-pyrrolidinyl)-6-(1S,4S)-2-oxa-5-azabicyclo(2.2.1)hept-5-yl-4-pyrimidinyl)-|CHEMBL3732012|SCHEMBL16210454|GTPL11506|GDC0134|SKMKJBYBPYBDMN-RYU |
---|---|
Specifications & Purity | Moligand™ |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of mitogen-activated protein kinase kinase kinase 12 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
INCHI | InChI=1S/C19H20F4N6O2/c20-17(21)31-14-3-10(6-25-16(14)24)13-5-15(29-7-12-4-11(29)8-30-12)27-18(26-13)28-2-1-19(22,23)9-28/h3,5-6,11-12,17H,1-2,4,7-9H2,(H2,24,25)/t11-,12-/m0/s1 |
---|---|
InChi Key | SKMKJBYBPYBDMN-RYUDHWBXSA-N |
Canonical SMILES | FC(Oc1cc(cnc1N)c1cc(nc(n1)N1CCC(C1)(F)F)N1C[C@@H]2C[C@H]1CO2)F |
Isomeric SMILES | C1CN(CC1(F)F)C2=NC(=CC(=N2)N3C[C@@H]4C[C@H]3CO4)C5=CC(=C(N=C5)N)OC(F)F |
PubChem CID | 86298636 |
PubChem CID | 86298636 |
---|---|
ChEMBL Ligand | CHEMBL3732012 |
Enter Lot Number to search for COA:
1. Villanueva MT. (2017) Neurodegenerative disease: DLK zips across neurodegeneration.. Nat Rev Drug Discov, 16 (10): (678-679). [PMID:28935914] |